OXYCODONE WOCKHARDT SOLUTION FOR INJECTION OR INFUSION 10MG/ML

Product Information

Registration Status: Active

OXYCODONE WOCKHARDT SOLUTION FOR INJECTION OR INFUSION 10MG/ML is approved to be sold in Singapore with effective from 2020-08-21. It is marketed by MEDIPHARM PTE LTD, with the registration number of SIN15996P.

This product contains Oxycodone 10.00 mg/mL in the form of INJECTION, SOLUTION. It is approved for INTRAVENOUS, SUBCUTANEOUS use.

This product is manufactured by CP Pharmaceuticals Limited in UNITED KINGDOM.

It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.

Oxycodone

Description

Oxycodone is a semisynthetic derivative of codeine that acts as a narcotic analgesic more potent and addicting than codeine. An extended-release (ER) form of oxycodone (Xtampza ER) was approved for the management of daily, around-the-clock pain management in April, 2016.

Indication

For the treatment of diarrhoea, pulmonary oedema and for the relief of moderate to moderately severe pain.

Mechanism of Action

Oxycodone acts as a weak agonist at mu, kappa, and delta opioid receptors within the central nervous system (CNS). Oxycodone primarily affects mu-type opioid receptors, which are coupled with G-protein receptors and function as modulators, both positive and negative, of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine, and noradrenaline is inhibited. Opioids such as oxycodone also inhibit the release of vasopressin, somatostatin, insulin, and glucagon. Opioids close N-type voltage-operated calcium channels (kappa-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (mu and delta receptor agonist). This results in hyperpolarization and reduced neuronal excitability.

Pharmacokinetics

Absorption
Well absorbed with an oral bioavailability of 60% to 87%
Distribution
* 2.6 L/kg
Metabolism
Hepatic
Elimination

Clearance

* 0.8 L/min [adults]

Toxicity

Symptoms of overdose include respiratory depression, somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, constricted pupils, bradycardia, hypotension, and death.

Active Ingredient/Synonyms

(-)-14-Hydroxydihydrocodeinone | 4,5-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one | 4,5alpha-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one | 4,5α-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one | Dihydro-14-hydroxycodeinone | Dihydrohydroxycodeinone | Dihydroxycodeinone | Oxicodona | Oxycodone | Oxycodonum | Oxycodone |


Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.

References

  1. Health Science Authority of Singapore - Reclassified POM
  2. Drugbank